Search

Your search keyword '"Tauer, Kurt"' showing total 48 results
Start Over Author "Tauer, Kurt"
48 results on '"Tauer, Kurt"'

1. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas, Dobelbower, Michael, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Swanson, Scott J, Stevenson, James, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Rare Diseases, Lung, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Humans, Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant, Pleural Neoplasms, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Published
2016

2. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Author

Ettinger, David S, Wood, Douglas E, Akerley, Wallace, Bazhenova, Lyudmila A, Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T, Chirieac, Lucian R, D'Amico, Thomas A, Dilling, Thomas J, Dobelbower, M Chris, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M, Komaki, Ritsuko, Lackner, Rudy P, Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W, Martins, Renato, Otterson, Gregory A, Patel, Jyoti D, Pisters, Katherine M, Reckamp, Karen, Riely, Gregory J, Schild, Steven E, Shapiro, Theresa A, Sharma, Neelesh, Stevenson, James, Swanson, Scott J, Tauer, Kurt, Yang, Stephen C, Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Cancer, Cancer, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Docetaxel, Humans, Immunosuppressive Agents, Immunotherapy, Lung Neoplasms, Nivolumab, Practice Guidelines as Topic, Survival Rate, Taxoids, Oncology & Carcinogenesis
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016

3. Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Author

Schwartzberg, Lee S, Tauer, Kurt W, Hermann, Robert C, Makari-Judson, Grace, Isaacs, Claudine, Beck, J Thaddeus, Kaklamani, Virginia, Stepanski, Edward J, Rugo, Hope S, Wang, Wei, Bell-McGuinn, Katherine, Kirshner, Jeffrey J, Eisenberg, Peter, Emanuelson, Richard, Keaton, Mark, Levine, Ellis, Medgyesy, Diana C, Qamar, Rubina, Starr, Alexander, Ro, Sunhee Kwon, Lokker, Nathalie A, and Hudis, Clifford A

Subjects
Cancer, Breast Cancer, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Breast Neoplasms, Capecitabine, Deoxycytidine, Disease Progression, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Fatigue, Female, Fluorouracil, Humans, Kaplan-Meier Estimate, Middle Aged, Niacinamide, Phenylurea Compounds, Receptor, ErbB-2, Skin Diseases, Sorafenib, Stomatitis, Treatment Outcome, Gemcitabine, Receptor, erbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab.Experimental designThis double-blind, randomized, placebo-controlled phase IIb study (ClinicalTrials.gov NCT00493636) enrolled patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer and prior bevacizumab treatment. Patients were randomized to chemotherapy with sorafenib (400 mg, twice daily) or matching placebo. Initially, chemotherapy was gemcitabine (1,000 mg/m(2) i.v., days 1, 8/21), but later, capecitabine (1,000 mg/m(2) orally twice daily, days 1-14/21) was allowed as an alternative. The primary endpoint was progression-free survival (PFS).ResultsOne hundred and sixty patients were randomized. More patients received gemcitabine (82.5%) than capecitabine (17.5%). Sorafenib plus gemcitabine/capecitabine was associated with a statistically significant prolongation in PFS versus placebo plus gemcitabine/capecitabine [3.4 vs. 2.7 months; HR = 0.65; 95% confidence interval (CI): 0.45-0.95; P = 0.02], time to progression was increased (median, 3.6 vs. 2.7 months; HR = 0.64; 95% CI: 0.44-0.93; P = 0.02), and overall response rate was 19.8% versus 12.7% (P = 0.23). Median survival was 13.4 versus 11.4 months for sorafenib versus placebo (HR = 1.01; 95% CI: 0.71-1.44; P = 0.95). Addition of sorafenib versus placebo increased grade 3/4 hand-foot skin reaction (39% vs. 5%), stomatitis (10% vs. 0%), fatigue (18% vs. 9%), and dose reductions that were more frequent (51.9% vs. 7.8%).ConclusionThe addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab. Combination treatment was associated with manageable toxicities but frequently required dose reductions.

Published
2013

4. Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Author

Schwartzberg, Lee S., primary, Tauer, Kurt W., primary, Hermann, Robert C., primary, Makari-Judson, Grace, primary, Isaacs, Claudine, primary, Beck, J. Thaddeus, primary, Kaklamani, Virginia, primary, Stepanski, Edward J., primary, Rugo, Hope S., primary, Wang, Wei, primary, Bell-McGuinn, Katherine, primary, Kirshner, Jeffrey J., primary, Eisenberg, Peter, primary, Emanuelson, Richard, primary, Keaton, Mark, primary, Levine, Ellis, primary, Medgyesy, Diana C., primary, Qamar, Rubina, primary, Starr, Alexander, primary, Ro, Sunhee Kwon, primary, Lokker, Nathalie A., primary, and Hudis, Clifford A., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 1 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Author

Schwartzberg, Lee S., primary, Tauer, Kurt W., primary, Hermann, Robert C., primary, Makari-Judson, Grace, primary, Isaacs, Claudine, primary, Beck, J. Thaddeus, primary, Kaklamani, Virginia, primary, Stepanski, Edward J., primary, Rugo, Hope S., primary, Wang, Wei, primary, Bell-McGuinn, Katherine, primary, Kirshner, Jeffrey J., primary, Eisenberg, Peter, primary, Emanuelson, Richard, primary, Keaton, Mark, primary, Levine, Ellis, primary, Medgyesy, Diana C., primary, Qamar, Rubina, primary, Starr, Alexander, primary, Ro, Sunhee Kwon, primary, Lokker, Nathalie A., primary, and Hudis, Clifford A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 3 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Author

Schwartzberg, Lee S., primary, Tauer, Kurt W., primary, Hermann, Robert C., primary, Makari-Judson, Grace, primary, Isaacs, Claudine, primary, Beck, J. Thaddeus, primary, Kaklamani, Virginia, primary, Stepanski, Edward J., primary, Rugo, Hope S., primary, Wang, Wei, primary, Bell-McGuinn, Katherine, primary, Kirshner, Jeffrey J., primary, Eisenberg, Peter, primary, Emanuelson, Richard, primary, Keaton, Mark, primary, Levine, Ellis, primary, Medgyesy, Diana C., primary, Qamar, Rubina, primary, Starr, Alexander, primary, Ro, Sunhee Kwon, primary, Lokker, Nathalie A., primary, and Hudis, Clifford A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 2 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Author

Schwartzberg, Lee S., primary, Tauer, Kurt W., primary, Hermann, Robert C., primary, Makari-Judson, Grace, primary, Isaacs, Claudine, primary, Beck, J. Thaddeus, primary, Kaklamani, Virginia, primary, Stepanski, Edward J., primary, Rugo, Hope S., primary, Wang, Wei, primary, Bell-McGuinn, Katherine, primary, Kirshner, Jeffrey J., primary, Eisenberg, Peter, primary, Emanuelson, Richard, primary, Keaton, Mark, primary, Levine, Ellis, primary, Medgyesy, Diana C., primary, Qamar, Rubina, primary, Starr, Alexander, primary, Ro, Sunhee Kwon, primary, Lokker, Nathalie A., primary, and Hudis, Clifford A., primary

Published
2023
Full Text
View/download PDF

14. Experiencing neutropenia: Quality of life interviews with adult cancer patients

Author

Okon Ted, Tauer Kurt W, Fortner Barry V, Houts Arthur C, and Schwartzberg Lee S

Subjects
Nursing, RT1-120
Abstract

Abstract Background Neutropenia is a common toxicity in chemotherapy but detailed information about how neutropenia is associated with changes in patients' quality of life is not readily available. This prospective study interviewed patients with grade 4 neutropenia to provide qualitative information on patients' experience of developing and coping with grade 4 neutropenia during a cycle of chemotherapy. Methods A sample of 34 patients who developed grade 4 neutropenia during the first cycle of chemotherapy completed a total of 100 structured clinical interviews. Interviews were transcribed, and 2 raters inductively developed 5 broad categories comprising 80 specific complaint domains nominated by patients. Thirty-five patient-nominated problems were mentioned in 5% or more of the interviews. Results Fatigue was the most common physical symptom. Interference in daily routine, negative self-evaluation, negative emotion, and social isolation were other common complaints associated with neutropenia. Conclusion Neutropenia is associated with a number of negative experiences among cancer patients undergoing chemotherapy, and these negative experiences have an adverse effect on the patient's quality of life. Oncology nurses can play a key role in helping patients manage adverse effects to maintain their quality of life.

Published
2005
Full Text
View/download PDF

15. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities

Author

Moore Kelley, Okon Theodore A, Zhu Ling, Tauer Kurt, Fortner Barry V, Templeton Davis, and Schwartzberg Lee

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects. Neutropenia, the most common dose-limiting toxicity of myelosuppressive chemotherapy, has substantial clinical and economic consequences. Colony-stimulating factors such as filgrastim and pegfilgrastim can reduce the incidence of neutropenia, but the clinic visits for these treatments can disrupt patients' routines and activities. Methods We surveyed patients to assess how clinic visits for treatment with chemotherapy and the management of neutropenia affect their time and activities. Results The mean amounts of time affected by these visits ranged from approximately 109 hours (hospitalization for neutropenia) and 8 hours (physician and chemotherapy) to less than 3 hours (laboratory and treatment with filgrastim or pegfilgrastim). The visits for filgrastim or pegfilgrastim were comparable in length, but treatment with filgrastim requires several visits per chemotherapy cycle and treatment with pegfilgrastim requires only 1 visit. Conclusions This study provides useful information for future modelling of additional factors such as disease status and chemotherapy schedule and provides information that should be considered in managing chemotherapy-induced neutropenia.

Published
2004
Full Text
View/download PDF

18. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Author

Ettinger, David S., primary, Aisner, Dara L., additional, Wood, Douglas E., additional, Akerley, Wallace, additional, Bauman, Jessica, additional, Chang, Joe Y., additional, Chirieac, Lucian R., additional, D'Amico, Thomas A., additional, Dilling, Thomas J., additional, Dobelbower, Michael, additional, Govindan, Ramaswamy, additional, Gubens, Matthew A., additional, Hennon, Mark, additional, Horn, Leora, additional, Lackner, Rudy P., additional, Lanuti, Michael, additional, Leal, Ticiana A., additional, Lilenbaum, Rogerio, additional, Lin, Jules, additional, Loo, Billy W., additional, Martins, Renato, additional, Otterson, Gregory A., additional, Patel, Sandip P., additional, Reckamp, Karen, additional, Riely, Gregory J., additional, Schild, Steven E., additional, Shapiro, Theresa A., additional, Stevenson, James, additional, Swanson, Scott J., additional, Tauer, Kurt, additional, Yang, Stephen C., additional, Gregory, Kristina, additional, and Hughes, Miranda, additional

Published
2018
Full Text
View/download PDF

19. Malignant Pleural Mesothelioma, Version 3.2016: Featured Updates to the NCCN Guidelines

Author

Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R., D’Amico, Thomas A., Dilling, Thomas, Dobelbower, Michael, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M., Komaki, Ritsuko, Lackner, Rudy P., Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W., Martins, Renato, Otterson, Gregory A., Patel, Jyoti D., Pisters, Katherine M., Reckamp, Karen, Riely, Gregory J., Schild, Steven E., Shapiro, Theresa A., Sharma, Neelesh, Swanson, Scott J., Stevenson, James, Tauer, Kurt, Yang, Stephen C., Gregory, Kristina, and Hughes, Miranda

Subjects
Mesothelioma, Lung Neoplasms, Pleural Neoplasms, Mesothelioma, Malignant, Humans, Article
Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Published
2016

20. NCCN Guidelines(®) Insights: Non–Small Cell Lung Cancer, Version 4.2016: Featured Updates to the NCCN Guidelines

Author

Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R., D’Amico, Thomas A., Dilling, Thomas J., Dobelbower, M. Chris, Govindan, Ramaswamy, Hennon, Mark, Horn, Leora, Jahan, Thierry M., Komaki, Ritsuko, Lackner, Rudy P., Lanuti, Michael, Lilenbaum, Rogerio, Lin, Jules, Loo, Billy W., Martins, Renato, Otterson, Gregory A., Patel, Jyoti D., Pisters, Katherine M., Reckamp, Karen, Riely, Gregory J., Schild, Steven E., Shapiro, Theresa A., Sharma, Neelesh, Stevenson, James, Swanson, Scott J., Tauer, Kurt, Yang, Stephen C., Gregory, Kristina, and Hughes, Miranda

Subjects
Lung Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Docetaxel, Antibodies, Monoclonal, Humanized, Article, Survival Rate, Nivolumab, Carcinoma, Non-Small-Cell Lung, Practice Guidelines as Topic, Carcinoma, Squamous Cell, Humans, Taxoids, Immunotherapy, Immunosuppressive Agents
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016

21. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Ettinger, David S., primary, Wood, Douglas E., additional, Aisner, Dara L., additional, Akerley, Wallace, additional, Bauman, Jessica, additional, Chirieac, Lucian R., additional, D'Amico, Thomas A., additional, DeCamp, Malcolm M., additional, Dilling, Thomas J., additional, Dobelbower, Michael, additional, Doebele, Robert C., additional, Govindan, Ramaswamy, additional, Gubens, Matthew A., additional, Hennon, Mark, additional, Horn, Leora, additional, Komaki, Ritsuko, additional, Lackner, Rudy P., additional, Lanuti, Michael, additional, Leal, Ticiana A., additional, Leisch, Leah J., additional, Lilenbaum, Rogerio, additional, Lin, Jules, additional, Loo, Billy W., additional, Martins, Renato, additional, Otterson, Gregory A., additional, Reckamp, Karen, additional, Riely, Gregory J., additional, Schild, Steven E., additional, Shapiro, Theresa A., additional, Stevenson, James, additional, Swanson, Scott J., additional, Tauer, Kurt, additional, Yang, Stephen C., additional, Gregory, Kristina, additional, and Hughes, Miranda, additional

Published
2017
Full Text
View/download PDF

22. The Memphis breast cancer disparity-screening program.

Author

Vidal, Gregory A., primary, Green, Zaquishia, additional, Tankersley, Cynthia, additional, Hidinger, Zachary, additional, Miranda, Rafael, additional, Baker, Bobby, additional, Jacobson, Paula, additional, Lamar, Kimberly, additional, Rafalski, Edward, additional, and Tauer, Kurt W., additional

Published
2015
Full Text
View/download PDF

23. Non–Small Cell Lung Cancer, Version 6.2015

Author

Ettinger, David S., primary, Wood, Douglas E., additional, Akerley, Wallace, additional, Bazhenova, Lyudmila A., additional, Borghaei, Hossein, additional, Camidge, David Ross, additional, Cheney, Richard T., additional, Chirieac, Lucian R., additional, D’Amico, Thomas A., additional, Demmy, Todd L., additional, Dilling, Thomas J., additional, Dobelbower, M. Chris, additional, Govindan, Ramaswamy, additional, Grannis, Frederic W., additional, Horn, Leora, additional, Jahan, Thierry M., additional, Komaki, Ritsuko, additional, Krug, Lee M., additional, Lackner, Rudy P., additional, Lanuti, Michael, additional, Lilenbaum, Rogerio, additional, Lin, Jules, additional, Loo, Billy W., additional, Martins, Renato, additional, Otterson, Gregory A., additional, Patel, Jyoti D., additional, Pisters, Katherine M., additional, Reckamp, Karen, additional, Riely, Gregory J., additional, Rohren, Eric, additional, Schild, Steven E., additional, Shapiro, Theresa A., additional, Swanson, Scott J., additional, Tauer, Kurt, additional, Yang, Stephen C., additional, Gregory, Kristina, additional, and Hughes, Miranda, additional

Published
2015
Full Text
View/download PDF

24. Non–Small Cell Lung Cancer, Version 1.2015

Author

Ettinger, David S., primary, Wood, Douglas E., additional, Akerley, Wallace, additional, Bazhenova, Lyudmila A., additional, Borghaei, Hossein, additional, Camidge, David Ross, additional, Cheney, Richard T., additional, Chirieac, Lucian R., additional, D’Amico, Thomas A., additional, Demmy, Todd L., additional, Dilling, Thomas J., additional, Govindan, Ramaswamy, additional, Grannis, Frederic W., additional, Horn, Leora, additional, Jahan, Thierry M., additional, Komaki, Ritsuko, additional, Kris, Mark G., additional, Krug, Lee M., additional, Lackner, Rudy P., additional, Lanuti, Michael, additional, Lilenbaum, Rogerio, additional, Lin, Jules, additional, Loo, Billy W., additional, Martins, Renato, additional, Otterson, Gregory A., additional, Patel, Jyoti D., additional, Pisters, Katherine M., additional, Reckamp, Karen, additional, Riely, Gregory J., additional, Rohren, Eric, additional, Schild, Steven, additional, Shapiro, Theresa A., additional, Swanson, Scott J., additional, Tauer, Kurt, additional, Yang, Stephen C., additional, Gregory, Kristina, additional, and Hughes, Miranda, additional

Published
2014
Full Text
View/download PDF

26. Effect of rituximab on outcomes in gastric B-cell lymphomas and on early mortality in gastric DLBCL.

Author

Wiedower, Eric, primary, Chandler, Jason Claud, additional, Pallera, Arnel M., additional, Johnson, Robert Alan, additional, Munene, Gitonga, additional, Dickson, Paxton, additional, Deneve, Jeremiah Lee, additional, Fleming, Martin D., additional, Tauer, Kurt W., additional, Schwartzberg, Lee Steven, additional, and Martin, Michael Gary, additional

Published
2014
Full Text
View/download PDF

29. Serum and tumor biomarkers to predict outcome in the eLung trial, a multicenter, randomized phase IIb study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC).

Author

Miller, Paul J. E., primary, Walker, Mark S., additional, Tauer, Kurt W., additional, Atkins, James, additional, Sivarajan, Kulumani M, additional, Patel, Vipul M., additional, Bastos, Bruno R., additional, Meyer, Krista, additional, Roder, Joanna, additional, Uyeda, Lisa, additional, Salazar, Suzanne, additional, Langer, Corey J., additional, Socinski, Mark A., additional, Spigel, David R., additional, and Schwartzberg, Lee Steven, additional

Published
2013
Full Text
View/download PDF

31. Thymomas and Thymic Carcinomas

Author

Ettinger, David S., primary, Riely, Gregory J., additional, Akerley, Wallace, additional, Borghaei, Hossein, additional, Chang, Andrew C., additional, Cheney, Richard T., additional, Chirieac, Lucian R., additional, D’Amico, Thomas A., additional, Demmy, Todd L., additional, Govindan, Ramaswamy, additional, Grannis, Frederic W., additional, Grant, Stefan C., additional, Horn, Leora, additional, Jahan, Thierry M., additional, Komaki, Ritsuko, additional, Kong, Feng-Ming (Spring), additional, Kris, Mark G., additional, Krug, Lee M., additional, Lackner, Rudy P., additional, Lennes, Inga T., additional, Loo, Billy W., additional, Martins, Renato, additional, Otterson, Gregory A., additional, Patel, Jyoti D., additional, Pinder-Schenck, Mary C., additional, Pisters, Katherine M., additional, Reckamp, Karen, additional, Rohren, Eric, additional, Shapiro, Theresa A., additional, Swanson, Scott J., additional, Tauer, Kurt, additional, Wood, Douglas E., additional, Yang, Stephen C., additional, Gregory, Kristina, additional, and Hughes, Miranda, additional

Published
2013
Full Text
View/download PDF

37. The Zero Acceptance of Pain (ZAP)™ Quality Improvement Project

Author

Fortner, Barry V., primary, Okon, Theodore A., additional, Ashley, Jeri, additional, Kepler, Ginney, additional, Chavez, Jana, additional, Tauer, Kurt, additional, Clements-Thompson, Michele, additional, Schwartzberg, Lee, additional, Demarco, Gail, additional, and Houts, Arthur C., additional

Published
2003
Full Text
View/download PDF

39. Adjuvant Dose-Intense Chemotherapy With Peripheral Blood Stem Cell Support in Stage II-III Breast Cancer With Five to Nine Involved Axillary Lymph Nodes

Author

Schwartzberg, Lee S., primary, Birch, Robert, additional, Tauer, Kurt W., additional, Leff, Richard, additional, Greco, F. Anthony, additional, Hainsworth, John, additional, Raefsky, Eric, additional, McAneny, Barbara, additional, Weaver, Zebulon, additional, West, John, additional, Buckner, C. Dean, additional, and Weaver, Charles H., additional

Published
1999
Full Text
View/download PDF

40. Sequential Treatment Including High-Dose Chemotherapy With Peripheral Blood Stem Cell Support in Patients With High-Risk Stage II-III Breast Cancer

Author

Schwartzberg, Lee S., primary, Birch, Robert, additional, West, William H., additional, Tauer, Kurt W., additional, Wittlin, Frederick, additional, Leff, Richard, additional, Campos, Luis, additional, Rymer, William, additional, Carter, Peter, additional, Mangum, Michael, additional, Greco, F. Anthony, additional, Hainsworth, John, additional, Raefsky, Eric, additional, Blanco, Rafael, additional, Buckner, C. Dean, additional, and Weaver, Charles H., additional

Published
1998
Full Text
View/download PDF

42. Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating Factor

Author

SCHWARTZBERG, LEE S., primary, BIRCH, ROBERT, additional, HAZELTON, BONNI, additional, TAUER, KURT W., additional, LEE, PAUL, additional, ALTEMOSE, RAND, additional, GEORGE, CHRISTOPHER, additional, BLANCO, RALPH, additional, WITTLIN, FRED, additional, COHEN, JAMES, additional, MUSCATO, JOSEPH, additional, and WEST, WILLIAM H., additional

Published
1992
Full Text
View/download PDF

43. The Zero Acceptance of Pain (ZAP)™ Quality Improvement Project: Evaluation of Pain Severity, Pain Interference, Global Quality of Life, and Pain-Related Costs

Author

Fortner, Barry V., Okon, Theodore A., Ashley, Jeri, Kepler, Ginney, Chavez, Jana, Tauer, Kurt, Clements-Thompson, Michele, Schwartzberg, Lee, Demarco, Gail, and Houts, Arthur C.

Subjects
*PAIN, *PAIN management, *CANCER pain, *QUALITY of life
Abstract

The Zero Acceptance of Pain (ZAP)™ Quality Improvement Project was a multi-site effort to improve the lives of outpatients with cancer pain by enhancing the clinical practice of pain assessment and management. Independent samples of patients completed self-report measures of severity of pain, pain interference, global quality of life, pain treatment satisfaction, general medical treatment satisfaction, pain attitudes, and pain-related medical costs before and after the implementation of ZAP. Results suggested that ZAP decreased the severity of recent pain, decreased interference of pain on daily functioning, and improved satisfaction with pain treatment and attitudes about addiction to opioid medication. Direct medical costs consisting of pain-related hospitalizations, emergency department visits, and physician office visits were greatly reduced. In summary, the findings of this study support the idea that clinic-based efforts to improve the practice of pain management are effective in improving the lives of cancer patients who are experiencing pain. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

44. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

Author

Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, and Hughes M

Subjects
Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung pathology, Humans, Lung Neoplasms immunology, Lung Neoplasms pathology, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Immunotherapy methods, Lung Neoplasms drug therapy, Practice Guidelines as Topic standards
Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."

Published
2019
Full Text
View/download PDF

45. Non-small cell lung cancer, version 2.2013.

Author

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, and Hughes M

Subjects
Humans, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms diagnosis, Lung Neoplasms therapy
Abstract

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail.

Published
2013
Full Text
View/download PDF

46. Baseline evaluation of assessment, information, and management patterns in a national quality improvement project.

Author

Johnson G, Fortner B, Moore K, Tauer KT, Zhu L, and Schwartzberg LS

Subjects
Anemia chemically induced, Anemia prevention & control, Antineoplastic Agents adverse effects, Depression chemically induced, Depression prevention & control, Diarrhea chemically induced, Diarrhea prevention & control, Female, Humans, Male, Middle Aged, Neoplasms complications, Neutropenia chemically induced, Neutropenia prevention & control, Pain chemically induced, Pain prevention & control, Program Development, United States, Vomiting chemically induced, Vomiting prevention & control, Delivery of Health Care organization & administration, Delivery of Health Care standards, Neoplasms drug therapy, Outcome and Process Assessment, Health Care, Program Evaluation, Total Quality Management
Published
2005

48. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.

Author

Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, and Houghton JA

Subjects
Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic therapeutic use, Antimetabolites, Antineoplastic toxicity, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Separation, Dose-Response Relationship, Drug, Female, Flow Cytometry, Fluorouracil toxicity, Follow-Up Studies, Humans, Interferon-gamma toxicity, Leucovorin toxicity, Lewis X Antigen biosynthesis, Male, Middle Aged, Models, Biological, Time Factors, Tumor Cells, Cultured, Up-Regulation, Colorectal Neoplasms drug therapy, Fluorouracil therapeutic use, Interferon-gamma pharmacokinetics, Interferon-gamma therapeutic use, Leucovorin therapeutic use, Signal Transduction, fas Receptor metabolism
Abstract

Potentiation of 5-fluorouracil/leucovorin (FUra/LV) cytotoxicity by IFN-gamma in colon carcinoma cells is dependent on FUra-induced DNA damage, the Fas death receptor, and independent of p53 and RNA-mediated FUra toxicity, which occurs in normal gastrointestinal tissues. This provides a rationale for enhancing the selective action of FUra/LV by IFN-gamma in the treatment of colorectal carcinoma. Based on results from our preclinical studies we designed a Phase I trial combining FUra (370 mg/m2) and LV (200 mg/m2), i.v. bolus daily x 5 days, with escalating doses of IFN-gamma (10-100 micro g/m2) s.c. on days 1, 3, and 5, every 28 days. Twenty-five patients with carcinomas were enrolled; 6 patients received IFN-gamma on days 1 and 3 only. The dose-limiting toxicity, stomatitis, occurred most frequently at 100 micro g/m2 IFN-gamma. Minor response or SD was observed in 2 of 9 patients and in 4 of 12 patients at dose levels of < or =50 micro g/m2 and > or =75 micro g/m2 IFN-gamma, respectively. Three evaluable chemonaive patients demonstrated partial response (2) or complete response (1). Serial plasma samples revealed peak FUra concentrations of >100 micro M; at 100 micro g/m2 IFN-gamma plasma concentrations >5 units/ml persisted for 6.5 h and >1 unit/ml for 28.5 h. The pharmacokinetic parameters of IFN-gamma correlated with a 2-3-fold up-regulation of Fas expression at 24 h in CD15+ cells in peripheral blood samples. Furthermore, clinically relevant IFN-gamma concentrations up-regulated Fas expression and sensitized HT29 colon carcinoma cells in vitro to FUra/LV cytotoxicity. On the basis of the modulation of Fas signaling, FUra/LV combined with IFN-gamma has shown activity in a Phase I trial in colorectal carcinoma and warrants additional evaluation in Phase II.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results